After scouring 200 companies’ pipelines — including a few overlooked pharma shelves — a new company backed by investment firm Population Health Partners and ARCH Venture Partners is launching with one of the most wide-ranging pipelines yet for obesity drug development.
Metsera came out of stealth mode Thursday with $290 million in seed and Series A financing. ARCH and Population Health Partners, which launched in 2020 and has several veterans from Pfizer and The Medicines Company on its team, led the round. F-Prime Capital, GV, Mubadala Capital, Newpath Partners, and SoftBank Vision Fund 2 were also part of the financing.
Metsera has already put that money to work: The New York startup licensed several drug candidates from South Korean biotech D&D Pharmatech, according to Endpoints and Korea Biomedical Review. Altogether, the deal is worth more than 1 trillion Korean won, or $740 million, in licensing fees and milestone payments.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect